Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Radiologie
Erschienen in: Der Radiologe 3/2014

01.03.2014 | Leitthema

Molekulare Brustbildgebung

Ein Update

verfasst von: K. Pinker, Prof. Dr. T.H. Helbich, MBA, MSc., H. Magometschnigg, B. Fueger, P. Baltzer

Erschienen in: Die Radiologie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Klinisches/methodisches Problem

Die molekulare Bildgebung zielt auf die Darstellung, Beschreibung und Quantifizierung biologischer, physiologischer und pathologischer Prozesse auf zellulärer und molekularer Ebene ab. In den letzten Jahren hat sich die molekulare Bildgebung mit ihren verschiedenen Modalitäten in der Brustdiagnostik etabliert.

Radiologische Standardverfahren

Die molekularen Brustbildgebung umfasst derzeit die multiparametrische(MP)-MRT mit funktioneller und morphologischer kontrastmittelverstärkter MRT (KM-MRT), molekularer diffusionsgewichteter Bildgebung („diffusion-weighted imaging“, DWI) und metabolischer Protonenspektroskopie (1H-MRSI) sowie nuklearmedizinische Verfahren (brustspezifische Gammakamerabildgebung [BSGI], Positronenemissionstomographie [PET], PET-Mammographie [PEM]) und kombinierte Verfahren (PET-CT, MP-PET-MRT).

Methodische Innovationen

Die molekulare Bildgebung in der Mammadiagnostik ist ein sich rapide entwickelndes Forschungsfeld mit neuen vielversprechenden Techniken wie der Natriumbildgebung (23Na-MRT), der Phosphorspektroskopie (31P-MRSI) und der hyperpolarisierten MRT sowie neuen zielgerichteten Radiotracern und Kontrastmitteln.

Bewertung

Der Einfluss der molekularen Brustbildgebung wird in den nächsten Jahren weiter zunehmen. Es ist zu erwarten, dass durch die molekulare Brustbildgebung eine optimierte Detektion und Charakterisierung von Brusttumoren, ein akkurates lokales und peripheres Staging sowie eine zielgerichtete Therapieverlaufskontrolle ermöglicht werden wird.
Literatur
1.
Ackerstaff E, Glunde K, Bhujwalla ZM (2003) Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90:525–533PubMed
2.
Adejolu M, Huo L, Rohren E et al (2012) False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol 198:W304–W314PubMed
3.
Aktolun C, Bayhan H, Kir M (1992) Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 17:171–176PubMed
4.
Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22:4357–4368PubMed
5.
Ardenkjaer-Larsen JH, Fridlund B, Gram A et al (2003) Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 100:10158–10163PubMedCentralPubMed
6.
Arias-Mendoza F, Payne GS, Zakian KL et al (2006) In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 19:504–512PubMed
7.
Arslan N, Ozturk E, Ilgan S et al (1999) 99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. Nucl Med Commun 20:317–325PubMed
8.
Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502PubMed
9.
Baltzer PA, Dietzel M (2013) Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T – systematic review and meta-analysis. Radiology 267:735–746PubMed
10.
Barzilai A, Horowitz A, Geier A et al (1991) Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 67:2919–2925PubMed
11.
Becherer A, Helbich T, Staudenherz A et al (1997) The diagnostic value of planar and SPET scintimammography in different age groups. Nucl Med Commun 18:710–718PubMed
12.
Been LB, Elsinga PH, De Vries J et al (2006) Positron emission tomography in patients with breast cancer using (18)F-3’-deoxy-3’-fluoro-l-thymidine ((18)F-FLT) – a pilot study. Eur J Surg Oncol 32:39–43PubMed
13.
Bensch F, Van Kruchten M, Lamberts LE et al (2013) Molecular imaging for monitoring treatment response in breast cancer patients. Eur J Pharmacol 717:2–11PubMed
14.
Berg WA, Madsen KS, Schilling K et al (2012) Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 198:219–232PubMed
15.
Berg WA, Weinberg IN, Narayanan D et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression („positron emission mammography“) is highly accurate in depicting primary breast cancer. Breast J 12:309–323PubMed
16.
Bickel H, Pinker K, Bogner W et al (2012) Diffusion-weighted imaging: a noninvasive biomarker for breast cancer invasiveness. RSNA, Chicago
17.
Birdwell RL, Mountford CE, Iglehart JD (2010) Molecular imaging of the breast. Radiol Clin North Am 48:1075–1088PubMed
18.
Blankenberg FG (2008) In vivo detection of apoptosis. J Nucl Med 49(Suppl 2):81S–95SPubMed
19.
Bogner W, Gruber S, Pinker K et al (2009) Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? Radiology 253:341–351PubMed
20.
Bogner W, Pinker-Domenig K, Bickel H et al (2012) Readout-segmented echo-planar imaging improves the diagnostic performance of diffusion-weighted MR breast examinations at 3.0 T. Radiology 263:64–76PubMed
21.
Brem RF, Fishman M, Rapelyea JA (2007) Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 14:945–950PubMed
22.
Brem RF, Floerke AC, Rapelyea JA et al (2008) Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 247:651–657PubMed
23.
Brem RF, Rapelyea JA, Zisman G et al (2005) Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology 237:274–280PubMed
24.
Brindle K (2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8:94–107PubMed
25.
Brindle KM, Bohndiek SE, Gallagher FA et al (2011) Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med 66:505–519PubMed
26.
Brown R, Storey P, Geppert C et al (2013) Breast MRI at 7 Tesla with a bilateral coil and T1-weighted acquisition with robust fat suppression: image evaluation and comparison with 3 Tesla. Eur Radiol 23:2969–2978PubMed
27.
Cheng J, Lei L, Xu J et al (2013) 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 54:333–340PubMed
28.
Cooper KL, Harnan S, Meng Y et al (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 37:187–198PubMed
29.
Coover LR, Caravaglia G, Kuhn P (2004) Scintimammography with dedicated breast camera detects and localizes occult carcinoma. J Nucl Med 45:553–558PubMed
30.
Cutrone JA, Khalkhali I, Yospur LS et al (1999) Tc-99m sestamibi scintimammography for the evaluation of breast masses in patients with radiographically dense breasts. Breast J 5:383–388PubMed
31.
Day SE, Kettunen MI, Cherukuri MK et al (2011) Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med 65:557–563PubMedCentralPubMed
32.
Domingues RC, Carneiro MP, Lopes FC et al (2009) Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol 192:1012–1020PubMed
33.
Ei Khouli RH, Jacobs MA, Mezban SD et al (2010) Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 256:64–73
34.
Escalona S, Blasco JA, Reza MM et al (2009) A systematic review of FDG-PET in breast cancer. Med Oncol 27:114–129PubMed
35.
Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508PubMed
36.
37.
Gallagher FA, Bohndiek SE, Kettunen MI et al (2011) Hyperpolarized 13C MRI and PET: in vivo tumor biochemistry. J Nucl Med 52:1333–1336PubMed
38.
Gallagher FA, Kettunen MI, Brindle KM (2011) Imaging pH with hyperpolarized 13C. NMR Biomed 24:1006–1015PubMed
39.
Glass SB, Shah ZA (2013) Clinical utility of positron emission mammography. Proceedings 26:314–319
40.
Golman K, Petersson JS (2006) Metabolic imaging and other applications of hyperpolarized 13C1. Acad Radiol 13:932–942PubMed
41.
Golman K, Zandt RI, Lerche M et al (2006) Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66:10855–10860PubMed
42.
Goto M, Ito H, Akazawa K et al (2007) Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features. J Magn Reson Imaging 25:104–112PubMed
43.
Gruber S, Debski BK, Pinker K et al (2011) Three-dimensional proton MR spectroscopic imaging at 3 T for the differentiation of benign and malignant breast lesions. Radiology 261:752–761PubMed
44.
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMed
45.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMed
46.
Helbich TH, Becherer A, Trattnig S et al (1997) Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. Radiology 202:421–429PubMed
47.
Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med14:459–465
48.
Kalinyak JE, Berg WA, Schilling K et al (2013) Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging [Epub ahead of print]
49.
Kalles V, Zografos GC, Provatopoulou X et al (2013) The current status of positron emission mammography in breast cancer diagnosis. Breast Cancer 20:123–130PubMed
50.
Kenny L, Coombes RC, Vigushin DM et al (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339–1347PubMed
51.
Keshari KR, Sai V, Wang ZJ et al (2013) Hyperpolarized [1–13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med 54:922–928PubMed
52.
Keshari KR, Sriram R, Koelsch BL et al (2013) Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Res 73:529–538PubMedCentralPubMed
53.
Khalkhali I, Mena I, Diggles L (1994) Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 21:357–362PubMed
54.
Klomp DW, Van De Bank BL, Raaijmakers A et al (2011) 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer. NMR Biomed 24:1337–1342PubMed
55.
Korteweg MA, Veldhuis WB, Visser F et al (2011) Feasibility of 7 Tesla breast magnetic resonance imaging determination of intrinsic sensitivity and high-resolution magnetic resonance imaging, diffusion-weighted imaging, and (1)H-magnetic resonance spectroscopy of breast cancer patients receiving neoadjuvant therapy. Invest Radiol 46:370–376PubMed
56.
Krause BJ, Schwarzenbock S, Schwaiger M (2010) Tracers in oncology – preclinical and clinical evaluation. Nuklearmedizin. Nuklearmedizin 49(Suppl 1):S41–S45PubMed
57.
Kuhl CK, Jost P, Morakkabati N et al (2006) Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 239:666–676PubMed
58.
Kuhl CK, Schild HH, Morakkabati N (2005) Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 236:789–800PubMed
59.
Kul S, Cansu A, Alhan E et al (2011) Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors. AJR Am J Roentgenol 196:210–217PubMed
60.
Kumar R, Lal N, Alavi A (2007) 18F-FDG PET in detecting primary breast cancer. J Nucl Med 48:1751 (author reply 1752)PubMed
61.
Kurhanewicz J, Vigneron DB, Brindle K et al (2011) Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 13:81–97PubMedCentralPubMed
62.
Linden HM, Dehdashti F (2013) Novel methods and tracers for breast cancer imaging. Semin Nucl Med 43:324–329PubMed
63.
Madelin G, Regatte RR (2013) Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging 38:511–529PubMed
64.
Maffioli L, Agresti R, Chiti A et al (1996) Prone scintimammography in patients with non-palpable breast lesions. Anticancer Res 16:1269–1273PubMed
65.
Martincich L, Deantoni V, Bertotto I et al (2012) Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol 22:1519–1528PubMed
66.
Mortimer JE, Bading JR, Colcher DM et al (2014) Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. J Nucl Med 55:23–29PubMed
67.
Moy L, Noz ME, Maguire GQ Jr et al (2007) Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans. Clin Nucl Med 32:194–198PubMed
68.
Moy L, Ponzo F, Noz ME et al (2007) Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med 48:528–537PubMed
69.
Ouwerkerk R (2011) Sodium MRI. Methods Mol Biol 711:175–201PubMed
70.
Ouwerkerk R, Jacobs MA, Macura KJ et al (2007) Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat 106:151–160PubMed
71.
72.
Partridge SC, Mullins CD, Kurland BF et al (2010) Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol 194:1664–1673PubMed
73.
Penuelas I, Dominguez-Prado I, Garcia-Velloso MJ et al (2012) PET tracers for clinical imaging of breast cancer. J Oncol 2012:710561PubMedCentralPubMed
74.
Pereira FP, Martins G, Carvalhaes De Oliveira Rde V (2011) Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin N Am 19:95–110PubMed
75.
Pichler BJ, Judenhofer MS, Wehrl HF (2008) PET/MRI hybrid imaging: devices and initial results. Eur Radiol 18:1077–1086PubMed
76.
Pinker K, Bickel H, Helbich T et al (2013) Combined contrast enhanced magnetic resonance and diffusion weighted imaging reading adapted to the „Breast Imaging Reporting and Data System“ for multiparametric 3 T imaging of breast lesions. Eur Radiol 23:1791–1802PubMed
77.
Pinker K, Bogner W, Baltzer P et al (2014) Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced MRI, diffusion-weighted imaging and 3D proton MR spectroscopic imaging. Invest Radiol (in press)
78.
Pinker K, Bogner W, Baltzer P et al (2013) Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7 T. Eur Radiol (in press)
79.
Pinker K, Bogner W, Gruber S et al (2011) Molecular imaging in breast cancer – potential future aspects. Breast Care (Basel) 6:110–119
80.
Pinker K, Grabner G, Bogner W et al (2009) A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol 44:553–558PubMed
81.
Pinker K, Magometschnigg H, Bogner W et al (2012) Multiparametric PET-MRI of breast tumors at 3 T obviates unnecessary breast biopsies. WMIC Dublin, Ireland
82.
Pinker K, Stadlbauer A, Bogner W et al (2012) Molecular imaging of cancer: MR spectroscopy and beyond. Eur J Radiol 81:566–577PubMed
83.
Pinker-Domenig K, Bogner W, Gruber S et al (2011) High resolution MRI of the breast at 3 T: which BI-RADS(R) descriptors are most strongly associated with the diagnosis of breast cancer? Eur Radiol 22:322–330PubMed
84.
Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23:1664–1673PubMed
85.
Rajendran JG (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252PubMed
86.
Rhodes DJ, O’connor MK, Phillips SW et al (2005) Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. Mayo Clin Proc 80:24–30PubMed
87.
Rosenkrantz AB, Deng FM, Kim S et al (2012) Prostate cancer: multiparametric MRI for index lesion localization – a multiple-reader study. AJR Am J Roentgenol 199:830–837PubMed
88.
Rosenkrantz AB, Mussi TC, Borofsky MS et al (2012) 3.0 T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy. Urol Oncol 31:1430–1435PubMed
89.
Roy B, Gupta RK, Maudsley AA et al (2013) Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology 55:603–310PubMed
90.
91.
Sauter AW, Wehrl HF, Kolb A et al (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16:508–515PubMed
92.
Sciarra A, Panebianco V, Cattarino S et al (2012) Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int 110:1661–1665PubMed
93.
Scopinaro F, Schillaci O, Ussof W et al (1997) A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. Anticancer Res 17:1631–1634PubMed
94.
Smith-Jones PM, Solit D, Afroze F et al (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793–796PubMedCentralPubMed
95.
Smith-Jones PM, Solit DB, Akhurst T et al (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701–706PubMed
96.
Stadlbauer A, Bernt R, Gruber S et al (2009) Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of malignant and benign breast lesions. Eur Radiol 19:2349–2356PubMed
97.
Stehouwer BL, Klomp DW, Korteweg MA et al (2013) 7 T versus 3 T contrast-enhanced breast magnetic resonance imaging of invasive ductulolobular carcinoma: first clinical experience. Magn Reson Imaging 31:613–617PubMed
98.
Stehouwer BL, Klomp DW, Van Den Bosch MA et al (2013) Dynamic contrast-enhanced and ultra-high-resolution breast MRI at 7.0 Tesla. Eur Radiol 23:2961–2968PubMed
99.
Sun Y, Wei W, Yang HW et al (2013) Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:450–463PubMed
100.
Taillefer R (2005) Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med 35:100–115PubMed
101.
Tamura K, Kurihara H, Yonemori K et al (2013) 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 54:1869–1875PubMed
102.
Umutlu L, Maderwald S, Kraff O et al (2010) Dynamic contrast-enhanced breast MRI at 7 Tesla utilizing a single-loop coil: a feasibility trial. Acad Radiol 17:1050–1056PubMed
103.
Van Kruchten M, De Vries EG, Brown M et al (2013) PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 14:e465–e475
104.
Vomweg TW, Teifke A, Schreiber WG et al (2002) Combination of low and high resolution T1-weighted sequences for improved evaluation of morphologic criteria in dynamic contrast enhanced MRI of the breast. Rofo 174:1445–1449PubMed
105.
Wang MW, Wang F, Zheng YJ et al (2013) An in vivo molecular imaging probe (18)F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation. Apoptosis 18:238–247PubMed
106.
Wehrl HF, Judenhofer MS, Wiehr S et al (2009) Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 36(Suppl 1):S56–S68PubMed
107.
Wehrl HF, Sauter AW, Judenhofer MS et al (2010) Combined PET/MR imaging – technology and applications. Technol Cancer Res Treat 9:5–20PubMed
108.
Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219:316–333PubMed
109.
Wijnen JP, Van Der Kemp WJ, Luttje MP et al (2011) Quantitative (31) P magnetic resonance spectroscopy of the human breast at 7 T. Magn Reson Med 68:339–348PubMed
110.
Woodhams R, Matsunaga K, Iwabuchi K et al (2005) Diffusion-weighted imaging of malignant breast tumors – the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Tomography 29:644–649
111.
Woodhams R, Matsunaga K, Kan S et al (2005) ADC mapping of benign and malignant breast tumors. J Magn Reson Med Sci 4:35–42
112.
Yabuuchi H, Matsuo Y, Kamitani T et al (2010) Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol 75:e126–e132PubMed
113.
Yabuuchi H, Matsuo Y, Okafuji T et al (2008) Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 28:1157–1165PubMed
114.
Yang Z, Sun Y, Zhang Y et al (2013) Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? Clin Breast Cancer 13:359–363PubMed
Metadaten
Titel
Molekulare Brustbildgebung
Ein Update
verfasst von
K. Pinker
Prof. Dr. T.H. Helbich, MBA, MSc.
H. Magometschnigg
B. Fueger
P. Baltzer
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Radiologie / Ausgabe 3/2014
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-013-2580-8

Weitere Artikel der Ausgabe 3/2014

Der Radiologe 3/2014 Zur Ausgabe

Leitthema

Therapiemonitoring im MRT unter neoadjuvanter Therapie

Einführung zum Thema

Mission „Mortalitätssenkung der häufigsten Krebserkrankung der Frau“

Leitthema

Mammographiescreening in Deutschland

Informationstechnologie und Management

Automatisierte Segmentierung und Annotation in der Radiologie

Leitthema

Zukunft mammographiebasierter Bildgebung

Quiz

Zervikalgie mit Erhöhung des C-reaktiven Proteins

Neu im Fachgebiet Radiologie

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise